OBJECTIVES: To propose a Bayesian approach to uncertainty analysis of sexually transmitted infection (STI) models, which can be used to quantify uncertainty in model assessments of policy options, estimate regional STI prevalence from sentinel surveillance data and make inferences about STI transmission and natural history parameters. METHODS: Prior distributions are specified to represent uncertainty regarding STI parameters. A likelihood function is defined using a hierarchical approach that takes account of variation between study populations, variation in diagnostic accuracy as well as random binomial variation. The method is illustrated using a model of syphilis, gonorrhoea, chlamydial infection and trichomoniasis in South Africa. RESULTS: Model estimates of STI prevalence are in good agreement with observations. Out-of-sample projections and cross-validations also show that the model is reasonably well calibrated. Model predictions of the impact of interventions are subject to significant uncertainty: the predicted reductions in the prevalence of syphilis by 2020, as a result of doubling the rate of health seeking, increasing the proportion of private practitioners using syndromic management protocols and screening all pregnant women for syphilis, are 43% (95% CI 3% to 77%), 9% (95% CI 1% to 19%) and 6% (95% CI 4% to 7%), respectively. CONCLUSIONS: This study extends uncertainty analysis techniques for fitted HIV/AIDS models to models that are fitted to other STI prevalence data. There is significant uncertainty regarding the relative effectiveness of different STI control strategies. The proposed technique is reasonable for estimating uncertainty in past STI prevalence levels and for projections of future STI prevalence.
OBJECTIVES: To propose a Bayesian approach to uncertainty analysis of sexually transmitted infection (STI) models, which can be used to quantify uncertainty in model assessments of policy options, estimate regional STI prevalence from sentinel surveillance data and make inferences about STI transmission and natural history parameters. METHODS: Prior distributions are specified to represent uncertainty regarding STI parameters. A likelihood function is defined using a hierarchical approach that takes account of variation between study populations, variation in diagnostic accuracy as well as random binomial variation. The method is illustrated using a model of syphilis, gonorrhoea, chlamydial infection and trichomoniasis in South Africa. RESULTS: Model estimates of STI prevalence are in good agreement with observations. Out-of-sample projections and cross-validations also show that the model is reasonably well calibrated. Model predictions of the impact of interventions are subject to significant uncertainty: the predicted reductions in the prevalence of syphilis by 2020, as a result of doubling the rate of health seeking, increasing the proportion of private practitioners using syndromic management protocols and screening all pregnant women for syphilis, are 43% (95% CI 3% to 77%), 9% (95% CI 1% to 19%) and 6% (95% CI 4% to 7%), respectively. CONCLUSIONS: This study extends uncertainty analysis techniques for fitted HIV/AIDS models to models that are fitted to other STI prevalence data. There is significant uncertainty regarding the relative effectiveness of different STI control strategies. The proposed technique is reasonable for estimating uncertainty in past STI prevalence levels and for projections of future STI prevalence.
Authors: Gabriela Paz-Bailey; Mafiz Rahman; Cheng Chen; Ronald Ballard; Howard J Moffat; Tom Kenyon; Peter H Kilmarx; Patricia A Totten; Sabina Astete; Marie Claude Boily; Caroline Ryan Journal: Clin Infect Dis Date: 2005-10-04 Impact factor: 9.079
Authors: Richard G White; Kate K Orroth; Eline L Korenromp; Roel Bakker; Mwita Wambura; Nelson K Sewankambo; Ron H Gray; Anatoli Kamali; James A G Whitworth; Heiner Grosskurth; J Dik F Habbema; Richard J Hayes Journal: J Acquir Immune Defic Syndr Date: 2004-12-01 Impact factor: 3.731
Authors: Robert L Cook; Shari L Hutchison; Lars Østergaard; R Scott Braithwaite; Roberta B Ness Journal: Ann Intern Med Date: 2005-06-07 Impact factor: 25.391
Authors: Richard G White; Kate K Orroth; Judith R Glynn; Esther E Freeman; Roel Bakker; J Dik F Habbema; Fern Terris-Prestholt; Lilani Kumaranayake; Anne Buvé; Richard J Hayes Journal: J Acquir Immune Defic Syndr Date: 2008-03-01 Impact factor: 3.731
Authors: Marie-Claude Boily; Benoît Mâsse; Ramzi Alsallaq; Nancy S Padian; Jeffrey W Eaton; Juan F Vesga; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Ben B Hui; Nathan Ryder; Jiunn-Yih Su; James Ward; Marcus Y Chen; Basil Donovan; Christopher K Fairley; Rebecca J Guy; Monica M Lahra; Mathew G Law; David M Whiley; David G Regan Journal: PLoS One Date: 2015-07-16 Impact factor: 3.240
Authors: Alethea W McCormick; Nadia N Abuelezam; Erin R Rhode; Taige Hou; Rochelle P Walensky; Pamela P Pei; Jessica E Becker; Madeline A DiLorenzo; Elena Losina; Kenneth A Freedberg; Marc Lipsitch; George R Seage Journal: PLoS One Date: 2014-05-27 Impact factor: 3.240
Authors: Ben B Hui; Richard T Gray; David P Wilson; James S Ward; Anthony M A Smith; David J Philip; Matthew G Law; Jane S Hocking; David G Regan Journal: BMC Infect Dis Date: 2013-04-25 Impact factor: 3.090
Authors: Jan A C Hontelez; Mark N Lurie; Till Bärnighausen; Roel Bakker; Rob Baltussen; Frank Tanser; Timothy B Hallett; Marie-Louise Newell; Sake J de Vlas Journal: PLoS Med Date: 2013-10-22 Impact factor: 11.069